News | April 17, 2025
Fortis Healthcare launches Fortis Institute of Genomic Medicine
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
More than 40 types of Amyloid proteins are discovered till date
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Plans underway to expand screening capacity by 50% for greater accessibility
Subscribe To Our Newsletter & Stay Updated
